Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3)

BACKGROUND: The endogenous opioid system is a fundamental regulator of mood in humans. Previously reported clinical trials have demonstrated the efficacy of the investigational agent buprenorphine/samidorphan (BUP/SAM) combination, an opioid-system modulator, for the adjunctive treatment of major de...

Descripción completa

Detalles Bibliográficos
Autores principales: Zajecka, John M, Stanford, Arielle D, Memisoglu, Asli, Martin, William F, Pathak, Sanjeev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459143/
https://www.ncbi.nlm.nih.gov/pubmed/31040679
http://dx.doi.org/10.2147/NDT.S199245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459143/
https://www.ncbi.nlm.nih.gov/pubmed/31040679
http://dx.doi.org/10.2147/NDT.S199245

Ejemplares similares